Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the recent results “a mixed quarter” and argued that the bar needs to come down before HIMS stock can work again.
The price target cut follows a Q1 2026 report that missed on both the top and bottom lines. Hims & Hers posted revenue of $608.1 million against a consensus of $616.85 million, and reported diluted EPS of -$0.40 versus the Street’s $0.03 expectation.
For prudent investors, Bank of America’s Hims & Hers downgrade signals a classic high-expectations reset rather than a fundamental shift in the thesis. HIMS stock traded at $23.85 intraday, well below the cut target.
| Ticker | Company | Firm | Action | Old Rating | New Rating | Old Target | New Target |
|---|---|---|---|---|---|---|---|
| HIMS | Hims & Hers Health | Bank of America | Price target cut | Neutral | Neutral | $32 | $30 |
The Analyst’s Case
Bank of America’s core argument is straightforward: Street assumptions are too high in the near term, and consensus models need to recalibrate. The firm believes the bar must reset before Hims & Hers stock can find traction.
That view sits in the middle of a divided Street. JPMorgan trimmed its HIMS stock price target to $33 from $35 while keeping an Overweight rating, and Canaccord actually raised its target to $32 from $30 with a Buy rating. The dispersion reflects genuine disagreement about how to value Hims & Hers after its strategic pivot.
Company Snapshot
Hims & Hers operates a multi-specialty telehealth platform connecting consumers with licensed clinicians across brands including Hims, Hers, ZAVA, and Labs. The company finished Q1 2026 with nearly 2.6 million subscribers, up 9% year over year.
The bigger story for Hims & Hers is the U.S. weight loss transition from compounded glucagon-like peptide-1 (GLP-1) drugs to branded alternatives. That shift drove $33.49 million in restructuring charges and weighed on U.S. revenue, which fell 8% year over year to $529.9 million.
Why the Move Matters Now
Compounded GLP-1s let Hims & Hers fill supply shortages, but branded products carry tighter regulatory standing and typically lower take rates for telehealth platforms. A tough year-over-year comparison against record weight loss ads makes even respectable growth look soft.
The valuation backdrop adds pressure. Hims & Hers stock trades at a trailing P/E ratio of 57x with a 67x forward earnings, and the average analyst target sits at $26.04. When sell-side estimates need to come down, the stock often drifts until the reset completes.
What It Means for Your Portfolio
The bull case for Hims & Hers rests on a subscription model that can expand beyond GLP-1s into broader categories, supported by a $250 million repurchase authorization and raised FY2026 revenue guidance of $2.8 billion to $3 billion. International revenue also surged 969% year over year.
The bear case is what Bank of America articulated: the bar is too high and needs to reset before HIMS stock can work. Hims & Hers’ gross margin compression to 65% from 73% and a swing to a $92.11 million net loss reinforce that concern.
For prudent investors, the takeaway is patience. Until consensus aligns with the post-pivot trajectory, Hims & Hers stock may need time to find stable footing, and moderate position sizing could prove sensible for those who like the long-term story.
Top Gaining Stocks
Top Losing Stocks